Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.
Looking for a particular Vaxxas employee's phone or email?
Vaxxas Questions
The Vaxxas annual revenue was $7 million in 2026.
David Peacock is the CEO of Vaxxas.
98 people are employed at Vaxxas.
Vaxxas is based in Brisbane, Queensland.
The NAICS codes for Vaxxas are [3254, 32, 325, 325414, 32541].
The SIC codes for Vaxxas are [28, 283].
Top Vaxxas Employees
-
David Peacock
Chief Executive Officer at Vaxxas
United States22 -
Angus Forster
Chief Technology Officer at Vaxxas
Brisbane City, QLD, AU22 -
Deborah Pascoe
Senior Vice President, CMC Development at Vaxxas
Brisbane, QLD, AU32 -
Thomas Lake
Chief Business Officer at Vaxxas
Philadelphia, PA, US25 -
Michael Larcom
Senior Vice President of Quality at Vaxxas
Brisbane City, QLD, AU1 -
Kevin Black
Head of Special Projects at Vaxxas
Washington, DC, US14 -
Michael Junger
Director - Industry and Government Relations at Vaxxas
Brisbane City, QLD, AU1 -
Jess Smith
Director at Vaxxas
Sydney, NSW, AU2 -
Elouise Comber
Business Development Analyst at Vaxxas
Brisbane City, QLD, AU2
Related Companies
